AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Q4 2024 revenue up 10%, with Screening segment leading with 14% growth.
- Full-year 2024 revenue of $2.76 billion, marking a 10% increase from 2023.
- Exact Sciences to launch three innovative cancer diagnostic tests in 2025.
Exact Sciences (NASDAQ:EXAS) has announced preliminary results for the fourth quarter of 2024, revealing strong revenue growth driven primarily by its Screening segment. The company anticipates total revenue of $713 million for Q4, marking a 10% increase year-over-year. Exact Sciences’ Screening segment continues to be a major contributor, with expected revenue of $553 million, a robust 14% growth compared to the same period last year. Precision Oncology, on the other hand, saw modest growth, with Q4 2024 revenue anticipated to reach $161 million, reflecting a 0.4% increase.
For the full year of 2024, Exact Sciences expects total revenue to reach $2.76 billion, representing a 10% increase compared to 2023. The Screening segment remains the primary growth driver, with projected revenue of $2.104 billion, up 13% year-over-year. Precision Oncology revenue is expected to increase by 4%, totaling $655 million for the full year.
Strong Performance in Screening Segment
The strong performance of Exact Sciences’ Screening segment, which includes products like Cologuard for colorectal cancer detection, continues to fuel the company’s overall growth. In Q4 2024, Screening revenue is expected to reach $553 million, a 14% increase compared to Q4 2023. This growth reflects continued demand for non-invasive cancer screening solutions, with Cologuard remaining a key product driving the company’s success.
In addition to its established screening tests, Exact Sciences is gearing up for significant product launches in 2025, including Cologuard Plus for enhanced colorectal cancer screening. This next-generation test is expected to provide more accurate results and improve patient outcomes, further cementing Exact Sciences’ leadership in the cancer diagnostics market.
Precision Oncology: Modest Growth
While Exact Sciences has seen significant growth in its Screening segment, its Precision Oncology division has experienced slower growth. The expected Q4 2024 revenue for Precision Oncology is $161 million, representing only a 0.4% increase from the previous year. Despite the modest growth in this segment, the company remains committed to expanding its oncology offerings, with future initiatives aimed at increasing its footprint in molecular residual disease detection and multi-cancer screening.
Exact Sciences continues to invest in expanding its Precision Oncology portfolio, with the planned launch of Oncodetect for molecular residual disease detection and Cancerguard for multi-cancer screening in 2025. These new tests are expected to significantly enhance the company’s position in oncology diagnostics and provide patients with more comprehensive and accurate cancer screening options.
Looking Ahead: New Product Launches in 2025
Exact Sciences’ pipeline for 2025 is particularly promising, with three new cancer diagnostic tests expected to be launched. The introduction of Cologuard Plus, Oncodetect, and Cancerguard will bolster the company’s position in the rapidly growing cancer diagnostics market. Cologuard Plus will offer enhanced colorectal cancer screening capabilities, while Oncodetect will target molecular residual disease, providing crucial insights into potential cancer recurrence. Cancerguard, designed for multi-cancer screening, has the potential to revolutionize early cancer detection and significantly improve patient outcomes.
